Literature DB >> 11716093

Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine.

M Simmons1, G S Murphy, T Kochel, K Raviprakash, C G Hayes.   

Abstract

A dengue-2 (DEN-2) DNA vaccine coding for the premembrane and envelope (E) proteins and a recombinant fusion protein containing the B domain of the DEN-2 E protein fused to the maltose-binding protein (MBP) of Escherichia coli both elicited neutralizing antibody in mice. In order to achieve more rapid protective immunity as well as to increase the persistence of neutralizing antibody, we primed mice with the DNA vaccine (D), the recombinant MBP protein (R), or both (RD) given simultaneously, and then boosted twice with either the R (R/R/R or D/R/R) or D (D/D/D or R/D/D) constructs alone or the RD (RD/RD/RD) combination. All of the recombinant protein vaccines were given with alum as an adjuvant. The serum antibody response measured by enzyme-linked immunosorbent assay was highest in D/D/D mice and RD/RD/RD mice. The D/R/R mice showed an intermediate response, and the R/D/D and R/R/R showed the lowest response. The geometric mean (GM) 50% neutralizationtiter (50% plaque reduction neutralization, or PRNT50) was marginally higher for RD/RD/RD mice (891) at 9 months after priming than that for R/R/R mice (724). T he lowest GM PRNT50 titers were seen in the D/D/D mice (33) and R/D/D mice (40), and the D/R/R group had a slightly higher titer (156) than these 2 groups. The predominant antibody subclass for the D/D/D mice was immunoglobulin (Ig) G2a, similar to mice infected with live virus. The R/R/R mice showed an exclusive IgGI antibody response, and the RD/RD/RD response also was predominantly IgGI. The antibody subclass pattern of the R/D/D and D/R/R mice showed a more balanced distribution of both IgG1 and IgG2a. Investigating the neutralizing capacity of antibody subclasses suggested that both IgG1 and IgG2a could neutralize DEN-2 virus. Our observations indicate that the combination RD prime-boost regimen warrants further investigation as a vaccine strategy to prevent dengue infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716093     DOI: 10.4269/ajtmh.2001.65.420

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

1.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

Review 2.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.

Authors:  Monika Simmons; Kevin R Porter; Curtis G Hayes; David W Vaughn; Robert Putnak
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells.

Authors:  Stefan Fernandez; Dupeh R Palmer; Monika Simmons; Peifang Sun; John Bisbing; Sasha McClain; Sachin Mani; Timothy Burgess; Vicky Gunther; Wellington Sun
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

5.  Nasal immunization with a fusion protein consisting of the hemagglutinin A antigenic region and the maltose-binding protein elicits CD11c(+) CD8(+) dendritic cells for induced long-term protective immunity.

Authors:  Yuan Du; Tomomi Hashizume; Tomoko Kurita-Ochiai; Satoshi Yuzawa; Yoshimitsu Abiko; Masafumi Yamamoto
Journal:  Infect Immun       Date:  2010-11-29       Impact factor: 3.441

6.  Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.

Authors:  Thomas J Chambers; Yan Liang; Deborah A Droll; Jacob J Schlesinger; Andrew D Davidson; Peter J Wright; Xiaoshan Jiang
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.

Authors:  Stacey L Demento; Nathalie Bonafé; Weiguo Cui; Susan M Kaech; Michael J Caplan; Erol Fikrig; Michel Ledizet; Tarek M Fahmy
Journal:  J Immunol       Date:  2010-07-26       Impact factor: 5.422

8.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

9.  A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.

Authors:  Lan Chen; Dan Ewing; Hemavathy Subramanian; Karla Block; Jonathan Rayner; Kimberly D Alterson; Martha Sedegah; Curtis Hayes; Kevin Porter; Kanakatte Raviprakash
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 10.  Dengue viral infections.

Authors:  G N Malavige; S Fernando; D J Fernando; S L Seneviratne
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.